Key Takeaways
- • Blue Owl's OBDC has marked down its second-lien loan to Loparex to 5 cents on the dollar (from 63 cents in March and 88 cents at year-end 2025), while its first-lien exposure collapsed to 22 cents from near par value, signaling acute credit deterioration.
- • Moody's Ratings has classified Loparex as in default with a Chapter 11 bankruptcy warning, following the collapse of a proposed M&A transaction that was intended to provide recapitalization and liquidity relief.
- • Loparex missed an interest payment on its second-lien debt in June and is operating under a forbearance agreement through September, with approximately $1.5bn in refinancing debt maturing in early 2027.
- • The sharp valuation write-down underscores emerging credit quality concerns across the $1.8 trillion private credit market and raises questions about mark-to-market discipline among institutional lenders.
- • OBDC President Logan Nicholson attributed the deterioration to the failed M&A transaction, which had been critical to strengthening the company's balance sheet and addressing its heavy debt burden.
Summary
Blue Owl Capital's public business development company has moved its loans to specialty materials manufacturer Loparex to non-accrual status following the second quarter, reflecting significant deterioration in credit quality and raising broader concerns about valuation practices in private credit. The decision came after Moody's Ratings classified Loparex as being in default and warned of potential Chapter 11 bankruptcy proceedings for the company, which is backed by Pamplona Capital Management.
The scale of the valuation collapse is striking. OBDC's second-lien exposure to Loparex was marked down to approximately 5 cents on the dollar at the end of the second quarter, down dramatically from 63 cents at the end of March and roughly 88 cents at the end of 2025. The first-lien loan, which had previously been carried at close to par value, was revalued at only around 22 cents on the dollar. These rapid deteriorations reflect the acute financial stress facing the company and the uncertainty surrounding recovery prospects for lenders.
The deterioration stems directly from the collapse of a proposed M&A transaction that Loparex had been pursuing to inject new equity and strengthen its balance sheet. According to OBDC President Logan Nicholson on the company's recent earnings call, the failed transaction had been essential to providing recapitalization and improved liquidity. Loparex had sought approximately $1.5 billion in refinancing from private credit lenders earlier in the year to address first- and second-lien borrowings, with maturity deadlines approaching in early 2027. The company missed an interest payment on its second-lien debt in June and is currently operating under a forbearance agreement through September, limiting its financial flexibility.
The Loparex situation highlights emerging credit quality challenges within the broader private credit market, valued at $1.8 trillion. The rapid mark-downs raise questions about the robustness of valuation methodologies and credit underwriting standards among major institutional lenders, particularly given the speed at which asset values have deteriorated over a six-month period.
The scale of the valuation collapse is striking. OBDC's second-lien exposure to Loparex was marked down to approximately 5 cents on the dollar at the end of the second quarter, down dramatically from 63 cents at the end of March and roughly 88 cents at the end of 2025. The first-lien loan, which had previously been carried at close to par value, was revalued at only around 22 cents on the dollar. These rapid deteriorations reflect the acute financial stress facing the company and the uncertainty surrounding recovery prospects for lenders.
The deterioration stems directly from the collapse of a proposed M&A transaction that Loparex had been pursuing to inject new equity and strengthen its balance sheet. According to OBDC President Logan Nicholson on the company's recent earnings call, the failed transaction had been essential to providing recapitalization and improved liquidity. Loparex had sought approximately $1.5 billion in refinancing from private credit lenders earlier in the year to address first- and second-lien borrowings, with maturity deadlines approaching in early 2027. The company missed an interest payment on its second-lien debt in June and is currently operating under a forbearance agreement through September, limiting its financial flexibility.
The Loparex situation highlights emerging credit quality challenges within the broader private credit market, valued at $1.8 trillion. The rapid mark-downs raise questions about the robustness of valuation methodologies and credit underwriting standards among major institutional lenders, particularly given the speed at which asset values have deteriorated over a six-month period.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.